Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Martín M, Ruiz Simón A, Ruiz Borrego M, Ribelles N, Rodríguez-Lescure Á, Muñoz-Mateu M, González S, Margelí Vila M, Barnadas A, Ramos M, Del Barco Berron S, Jara C, Calvo L, Martínez-Jáñez N, Mendiola Fernández C, Rodríguez CA, Martínez de Dueñas E, Andrés R, Plazaola A, de la Haba-Rodríguez J, López-Vega JM, Adrover E, Ballesteros AI, Santaballa A, Sánchez-Rovira P, Baena-Cañada JM, Casas M, del Carmen Cámara M, Carrasco EM, Lluch A. Martín M, et al. Among authors: calvo l. J Clin Oncol. 2015 Nov 10;33(32):3788-95. doi: 10.1200/JCO.2015.61.9510. Epub 2015 Sep 28. J Clin Oncol. 2015. PMID: 26416999 Clinical Trial.
Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial.
Pelegrí A, Calvo L, Mayordomo JI, Florián J, Vázquez S, Arcusa A, Martn-Richard M, Bayo JL, Virizuela J, Carrasco E, Antón A; Spanish Group for Breast Cancer Research (GEICAM). Pelegrí A, et al. Among authors: calvo l. Semin Oncol. 2004 Apr;31(2 Suppl 5):20-4. doi: 10.1053/j.seminoncol.2004.03.023. Semin Oncol. 2004. PMID: 15199528 Clinical Trial.
Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial.
Pelegrí A, Calvo L, Antón A, Mayordomo JI, Florián J, Vásquez S, Arcusa A, Martín-Richard M, Bayo JL, Carrasco E, Virizuela J; Spanish Group for Breast Cancer Research (GEICAM). Pelegrí A, et al. Among authors: calvo l. Clin Breast Cancer. 2005 Dec;6(5):433-8. doi: 10.3816/cbc.2005.n.048. Clin Breast Cancer. 2005. PMID: 16381627 Clinical Trial.
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Martín M, Lluch A, Seguí MA, Ruiz A, Ramos M, Adrover E, Rodríguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacón C, Roset M, Antón A, Isla D, del Prado PM, Iglesias L, Zaluski J, Arcusa A, López-Vega JM, Muñoz M, Mel JR. Martín M, et al. Among authors: calvo l. Ann Oncol. 2006 Aug;17(8):1205-12. doi: 10.1093/annonc/mdl135. Epub 2006 Jun 9. Ann Oncol. 2006. PMID: 16766587 Free article. Clinical Trial.
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
Martín M, Ruiz A, Muñoz M, Balil A, García-Mata J, Calvo L, Carrasco E, Mahillo E, Casado A, García-Saenz JA, Escudero MJ, Guillem V, Jara C, Ribelles N, Salas F, Soto C, Morales-Vasquez F, Rodríguez CA, Adrover E, Mel JR; Spanish Breast Cancer Research Group (GEICAM) trial. Martín M, et al. Among authors: calvo l. Lancet Oncol. 2007 Mar;8(3):219-25. doi: 10.1016/S1470-2045(07)70041-4. Lancet Oncol. 2007. PMID: 17329192 Clinical Trial.
Time-to-progression in breast cancer: a stratification model for clinical trials.
de la Haba-Rodríguez J, Aranda E, Llombart A, Lluch A, Alba E, Munárriz B, Adrover E, Tusquets I, Balil A, Barnadas A, Calvo L, Martín M; Grupo Español de Investigación en Cáncer de Mama (GEICAM). de la Haba-Rodríguez J, et al. Among authors: calvo l. Breast. 2008 Jun;17(3):239-44. doi: 10.1016/j.breast.2007.09.007. Epub 2007 Nov 26. Breast. 2008. PMID: 18042386
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.
Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, Calvo L, Carabantes F, Crespo C, Muñoz M, Llombart A, Plazaola A, Artells R, Gilabert M, Lloveras B, Alba E. Colomer R, et al. Among authors: calvo l. Clin Cancer Res. 2008 Feb 1;14(3):811-6. doi: 10.1158/1078-0432.CCR-07-1923. Clin Cancer Res. 2008. PMID: 18245543
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Barnadas A, Gil M, Sánchez-Rovira P, Llombart A, Adrover E, Estevez LG, de la Haba J, Calvo L. Barnadas A, et al. Among authors: calvo l. Anticancer Drugs. 2008 Apr;19(4):339-47. doi: 10.1097/CAD.0b013e3282f97f75. Anticancer Drugs. 2008. PMID: 18454044 Review.
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators. Martín M, et al. Among authors: calvo l. J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27. J Natl Cancer Inst. 2008. PMID: 18505968 Free article. Clinical Trial.
Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial.
Del Barco S, Colomer R, Calvo L, Tusquets I, Adrover E, Sánchez P, Rifà J, De la Haba J, Virizuela JA. Del Barco S, et al. Among authors: calvo l. Breast Cancer Res Treat. 2009 Jul;116(2):351-8. doi: 10.1007/s10549-008-0218-8. Epub 2008 Oct 22. Breast Cancer Res Treat. 2009. PMID: 18941891 Clinical Trial.
344 results